Literature DB >> 18361452

Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.

Hara Levy1, Leslie A Kalish, Carolyn L Cannon, K Christopher García, Craig Gerard, Don Goldmann, Gerald B Pier, Scott T Weiss, A A Colin.   

Abstract

RATIONALE: Chronic mucoid Pseudomonas aeruginosa within the airway in cystic fibrosis (CF) patients can determine prognosis. Understanding the risk factors of mucoid P. aeruginosa acquisition may change how we deliver care. This study aims to evaluate whether presence of risk factors reported to predict disease severity including gender, CFTR genotype, bacterial organisms in airway cultures, and serum levels of vitamins A and E, albumin, C-reactive protein, alpha 1-antitrypsin, and immunoglobulins increased the risk of mucoid P. aeruginosa acquisition.
METHODS: Primary endpoint was age at first transition from negative to positive culture for mucoid P. aeruginosa. Cox proportional hazards regression with time-dependent covariates examined development of mucoid P. aeruginosa infection and its association with longitudinally measured serum biomarkers, pulmonary function, and culture results for other organisms.
RESULTS: Median ages at CF diagnosis and at first culture were 0.55 and 5.7 years, respectively. Median number of cultures/patient was 17. Of the 323 subjects, 150 developed mucoid P. aeruginosa during a median 8.1 years' follow-up. In multivariate analysis, gender (relative hazard [RH] 0.55 for male vs. female, P = 0.001), number of DF508 alleles (RH 1.66 for 1 or 2 vs. 0, P = 0.04), FEV(1) % (RH 1.16 for 10% decrease, P = 0.008), and most recent Staphylococcus aureus status (RH 0.24 for positive vs. negative, P < 0.0001) remained statistically significant.
CONCLUSION: Female gender, number of DF508 alleles, decreased lung function, and lack of S. aureus on recent sputum culture are important risk factors for early detection of mucoid P. aeruginosa. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18361452      PMCID: PMC3693457          DOI: 10.1002/ppul.20794

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  33 in total

1.  Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis.

Authors:  P M Farrell; G Shen; M Splaingard; C E Colby; A Laxova; M R Kosorok; M J Rock; E H Mischler
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

Review 2.  Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?

Authors:  Alan Smyth
Journal:  Pediatr Pulmonol       Date:  2005-12

Review 3.  CF-Emerging therapies: Modulation inflammation.

Authors:  M Fayon
Journal:  Paediatr Respir Rev       Date:  2006-06-05       Impact factor: 2.726

4.  Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.

Authors:  Ronald L Gibson; Julia Emerson; Nicole Mayer-Hamblett; Jane L Burns; Sharon McNamara; Frank J Accurso; Michael W Konstan; Barbara A Chatfield; George Retsch-Bogart; David A Waltz; James Acton; Pamela Zeitlin; Peter Hiatt; Richard Moss; Judy Williams; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2007-07

5.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

6.  Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

Authors:  D S Armstrong; K Grimwood; J B Carlin; R Carzino; A Olinsky; P D Phelan
Journal:  Pediatr Pulmonol       Date:  1996-05

7.  Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis.

Authors:  J Schneiderman-Walker; D L Wilkes; L Strug; L C Lands; S L Pollock; H C Selvadurai; J Hay; A L Coates; M Corey
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

8.  Inflammatory markers of lung disease in adult patients with cystic fibrosis.

Authors:  Hara Levy; Leslie A Kalish; Ian Huntington; Nathaniel Weller; Craig Gerard; Edwin K Silverman; Juan C Celedón; Gerald B Pier; Scott T Weiss
Journal:  Pediatr Pulmonol       Date:  2007-03

9.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

10.  Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.

Authors:  Miriam M Treggiari; Margaret Rosenfeld; George Retsch-Bogart; Ron Gibson; Bonnie Ramsey
Journal:  Pediatr Pulmonol       Date:  2007-09
View more
  17 in total

1.  Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.

Authors:  Jerry A Nick; Cathy S Chacon; Sara J Brayshaw; Marion C Jones; Christine M Barboa; Connie G St Clair; Robert L Young; David P Nichols; Jennifer S Janssen; Gwen A Huitt; Michael D Iseman; Charles L Daley; Jennifer L Taylor-Cousar; Frank J Accurso; Milene T Saavedra; Marci K Sontag
Journal:  Am J Respir Crit Care Med       Date:  2010-05-06       Impact factor: 21.405

2.  Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  J Cyst Fibros       Date:  2019-04-26       Impact factor: 5.482

3.  Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease.

Authors:  Jessica E Pittman; Elizabeth H Calloway; Michelle Kiser; John Yeatts; Stephanie D Davis; Mitchell L Drumm; Michael S Schechter; Margaret W Leigh; Mary Emond; Annelies Van Rie; Michael R Knowles
Journal:  Pediatr Pulmonol       Date:  2010-12-30

4.  Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.

Authors:  Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Valeria Thompson; Bonnie W Ramsey; Wayne Morgan; Ronald L Gibson
Journal:  J Cyst Fibros       Date:  2012-05-01       Impact factor: 5.482

5.  Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Robert Bradley Troxler; Wynton C Hoover; LaCrecia J Britton; Andrea M Gerwin; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2012-04-11

6.  The Estrogen-Induced miR-19 Downregulates Secretory Leucoprotease Inhibitor Expression in Monocytes.

Authors:  Paul J McKiernan; Stephen G J Smith; Andrew L Durham; Ian M Adcock; Noel G McElvaney; Catherine M Greene
Journal:  J Innate Immun       Date:  2019-07-02       Impact factor: 7.349

7.  Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.

Authors:  Claire L Keating; Xinhua Liu; Emily A Dimango
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

8.  Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Authors:  S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2017-10-28       Impact factor: 5.482

9.  Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation.

Authors:  Troy D Pashuck; Sarah E Franz; Molly K Altman; Clive H Wasserfall; Mark A Atkinson; Thomas J Wronski; Terence R Flotte; Michael S Stalvey
Journal:  Pediatr Res       Date:  2009-03       Impact factor: 3.756

10.  Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.

Authors:  P Vidya; L Smith; T Beaudoin; Y C Yau; S Clark; B Coburn; D S Guttman; D M Hwang; V Waters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.